PATENT CLAIM ANALYSIS

Application Number: 15923011
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["424", "139100"]

Abstract:
Monoclonal anti-PHF-tau antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies and using the antibodies for treating or preventing conditions such as tauopathies.

Claim (Index 3):
The isolated monoclonal antibody or antigen-binding fragment of  claim 2  comprising:\n (a) immunoglobulin heavy chain complementarity determining regions (HCDRs) HCDR1, HCDR2 and HCDR3 having the polypeptide sequences of SEQ ID NOs: 7, 8 and 9, respectively and immunoglobulin light chain complementarity determining regions (LCDRs) LCDR1, LCDR2 and LCDR3 having the polypeptide sequences of SEQ ID NOs: 19, 20 and 21, respectively; \n (b) HCDR1, HCDR2 and HCDR3 having the polypeptide sequences of SEQ ID NOs: 1, 2 and 3, respectively and LCDR1, LCDR2 and LCDR3 having the polypeptide sequences of SEQ ID NOs: 13, 14 and 15, respectively; \n (c) HCDR1, HCDR2 and HCDR3 having the polypeptide sequences of SEQ ID NOs: 4, 5 and 6, respectively and LCDR1, LCDR2 and LCDR3 having the polypeptide sequences of SEQ ID NOs: 16, 17 and 18, respectively; \n (d) HCDR1, HCDR2 and HCDR3 having the polypeptide sequences of SEQ ID NOs: 10, 11 and 12, respectively and LCDR1, LCDR2 and LCDR3 having the polypeptide sequences of SEQ ID NOs: 22, 23 and 24, respectively; \n (e) HCDR1, HCDR2 and HCDR3 having the polypeptide sequences of SEQ ID NOs:80, 81 and 9, respectively and LCDR1, LCDR2 and LCDR3 having the polypeptide sequences of SEQ ID NOs: 70, 20 and 21, respectively; \n (f) HCDR1, HCDR2 and HCDR3 having the polypeptide sequences of SEQ ID NOs: 71, 72, 73, respectively and LCDR1, LCDR2 and LCDR3 having the polypeptide sequences of SEQ ID NOs: 70, 20 and 21, respectively; \n (g) HCDR1, HCDR2 and HCDR3 having the polypeptide sequences of SEQ ID NOs: 71, 72 and 73, respectively and LCDR1, LCDR2 and LCDR3 having the polypeptide sequences of SEQ ID NOs: 19, 20 and 21, respectively; \n (h) HCDR1, HCDR2 and HCDR3 of a V H  region having the polypeptide sequence of SEQ ID NO: 26 and LCDR1, LCDR2 and LCDR3 of a V L  region having the polypeptide sequence of SEQ ID NO: 31; \n (i) HCDR1, HCDR2 and HCDR3 of a V H  region having the polypeptide sequence of SEQ ID NO: 28 and LCDR1, LCDR2 and LCDR3 of a V L  region having the polypeptide sequence of SEQ ID NO: 34; \n (j) HCDR1, HCDR2 and HCDR3 of a V H  region having the polypeptide sequence of SEQ ID NO: 26 and LCDR1, LCDR2 and LCDR3 of a V L  region having the polypeptide sequence of SEQ ID NO: 34; or \n (k) HCDR1, HCDR2 and HCDR3 of a V H  region having the polypeptide sequence of SEQ ID NO: 28 and LCDR1, LCDR2 and LCDR3 of a V L  region having the polypeptide sequence of SEQ ID NO: 31;\n wherein the antibody or antigen-binding fragment thereof binds PHF-tau.

Metadata:
- Claim Count in Document: 18.0
- Percentile: 90.0
- Lexical Diversity: 1.4
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13716526', '14309330', '15559791', '15818090', '14774512']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8042586173537404
- 35 USC 102 Novelty (BERT): 0.5779331999493986
- Combined Prediction Score: 0.7816260756133062
- Mean Citation Score: 493.22498800000005
- Max Citation Score: 508.12195
- Similarity Product: 409.64556770457625

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test